BREAST CANCER SUBTYPES IN PAKISTANI POPULATION: DATA FROM A SINGLE CENTER

K BANO; S RIAZ; A ZAFAR; F SHEIKH; AA RASHID; Z ISMAIL

doi:10.54112/bcsrj.v2023i1.540

Authors

K BANO Department of Oncology, Jinnah Hospital Lahore, Pakistan
S RIAZ Department of Oncology, Life Care Hospital Lahore, Pakistan
A ZAFAR Department of Oncology, Jinnah Hospital Lahore, Pakistan
F SHEIKH Department of Oncology, Jinnah Hospital Lahore, Pakistan
AA RASHID Department of Oncology, University of Lahore Teaching Hospital/University College of Medicine and Dentistry Lahore Pakistan
Z ISMAIL Department of Oncology, Hameed Latif Hospital Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.540

Keywords:

Breast Cancer, Estrogen, Progesterone, HER2neu Expression

Abstract

Breast cancer is a complex disease that includes different types of tumors. These tumors can vary in their characteristics, such as the levels of estrogen, progesterone, and HER2/neu receptors. These differences can impact how the tumors respond to treatment, progress, and change over time. The study conducted at the Department of Oncology, Jinnah Hospital, Lahore, from May to November 2019, was a cross-sectional study that involved 90 female patients with breast cancer aged 25 to 75. The researchers analyzed the tumor samples using immunohistochemistry to evaluate ER, PR, and HER2neu levels. FISH was used to evaluate models that had equivocal HER2 by IHC. The participants in this study were 25 to 75 years old, with an average age of 47.10 ± 11.55 years. The average duration of the disease before presenting to the hospital was 6.71 ± 2.63 months. The study found that 74.44% of the female patients had tumors that were ER-positive, 56.67% had tumors that were PR-positive, and 20.0% had tumors that were HER2neu-positive. In conclusion, this study showed that the frequency of positive expression of estrogen, progesterone, and HER2neu in breast cancer patients in this population was consistent with international rates. However, more extensive studies are necessary to determine the exact prevalence of these tumors.

Downloads

Download data is not yet available.

References

Allred, D., Harvey, J. M., Berardo, M., and Clark, G. M. (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 11, 155-168.

Dawson, S.-J., Makretsov, N., Blows, F., Driver, K., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G., and McLean, C. A. (2010). BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British journal of cancer 103, 668-675.

Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., and Narod, S. A. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical cancer research 13, 4429-4434.

Fritz, M. A., and Speroff, L. (2011). "Clinical gynecologic endocrinology and infertility," lippincott Williams & wilkins.

Gadkar-Sable, S., Shah, C., Rosario, G., Sachdeva, G., and Puri, C. (2005). Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci 10, 30.

Greene, G. L., Nolan, C., Engler, J. P., and Jensen, E. V. (1980). Monoclonal antibodies to human estrogen receptor. Proceedings of the National Academy of Sciences 77, 5115-5119.

Kamil, M., Khalid, I., Hashim, H., Biswas, M., Kaur, G., and Islam, R. (2010). Association of carcinoma breast: grade and estrogen progesterone receptor expression. J Coll Physicians Surg Pak 20, 250-2.

King, W., and Greene, G. L. (1984). Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307, 745-747.

Knight III, W. A., Livingston, R. B., Gregory, E. J., and McGuire, W. L. (1977). Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer research 37, 4669-4671.

Kroese, M., Zimmern, R. L., and Pinder, S. E. (2007). HER2 status in breast cancer–an example of pharmacogenetic testing. Journal of the Royal Society of Medicine 100, 326-329.

Law, M. L., Kao, F., Wei, Q., Hartz, J., Greene, G., Zarucki-Schulz, T., Conneely, O., Jones, C., Puck, T., and O'Malley, B. (1987). The progesterone receptor gene maps to human chromosome band 11q13, the site of the mammary oncogene int-2. Proceedings of the National Academy of Sciences 84, 2877-2881.

Marcuzzo, T., Giudici, F., Ober, E., Rizzardi, C., Bottin, C., and Zanconati, F. (2016). Her2 immunohistochemical evaluation by traditional microscopy and by digital analysis, and the consequences for FISH testing. Pathology-Research and Practice 212, 911-918.

McGuire, W. L. (1991). Breast cancer prognostic factors: evaluation guidelines. Vol. 83, pp. 154-155. Oxford University Press.

Misrahi, M., Atger, M., d'Auriol, L., Loosfelt, H., Meriel, C., Fridlansky, F., Guiochon-Mantel, A., Galibert, F., and Milgrom, E. (1987). Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochemical and biophysical research communications 143, 740-748.

Mouttet, D., Laé, M., Caly, M., Gentien, D., Carpentier, S., Peyro-Saint-Paul, H., Vincent-Salomon, A., Rouzier, R., Sigal-Zafrani, B., and Sastre-Garau, X. (2016). Estrogen-receptor, progesterone-receptor and HER2 status determination in invasive breast cancer. Concordance between immuno-histochemistry and MapQuant™ microarray based assay. PLoS One 11, e0146474.

Okuyama Kishima, M., Oliveira, C. E. C. d., Banin-Hirata, B. K., Losi-Guembarovski, R., Brajão de Oliveira, K., Amarante, M. K., and Watanabe, M. A. E. (2015). Immunohistochemical expression of CXCR4 on breast cancer and its clinical significance. Analytical Cellular Pathology 2015.

Oncology, A. S. o. C. (1996). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14, 2843-2877.

Onitilo, A. A., Engel, J. M., Greenlee, R. T., and Mukesh, B. N. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical medicine & research 7, 4-13.

Pervaiz, F., Rehmani, S., Majid, S., and Anwar, H. (2015). Evaluation of hormone receptor status (ER/PR/HER2-neu) in breast cancer in Pakistan. FEC 99, 47.

Peters, J. A. (1997). Applications of genetic technologies to cancer screening, prevention, diagnosis, prognosis, and treatment. In "Seminars in oncology nursing", Vol. 13, pp. 74-81. Elsevier.

Puvitha, R., and Shifa, S. (2016). Breast Carcinoma, Receptor Status, and Her2 neu Overexpression Revisited``. International Journal of Scientific Study 3, 52-58.

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer Jr, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., and Kaufman, P. A. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England journal of medicine 353, 1673-1684.

Safarpour, D., Pakneshan, S., and Tavassoli, F. A. (2014). Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? American journal of cancer research 4, 353.

Saini, K., Taylor, C., Ramirez, A.-J., Palmieri, C., Gunnarsson, U., Schmoll, H.-J., Dolci, S., Ghenne, C., Metzger-Filho, O., and Skrzypski, M. (2012). Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Annals of oncology 23, 853-859.

Sariego, J. (2010). Breast cancer in the young patient. The American surgeon 76, 1397-1400.

Sotiriou, C., and Pusztai, L. (2009). Gene-expression signatures in breast cancer. New England Journal of Medicine 360, 790-800.

Sughayer, M. A., Al-Khawaja, M. M., Massarweh, S., and Al-Masri, M. (2006). Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathology & Oncology Research 12, 83-86.

Tarulli, G. A., Butler, L. M., Tilley, W. D., and Hickey, T. E. (2014). Bringing androgens up a NOTCH in breast cancer. Endocrine-related cancer 21, T183-T202.